These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 11249520)
1. Orlistat in the treatment of obesity. Ballinger A Expert Opin Pharmacother; 2000 May; 1(4):841-7. PubMed ID: 11249520 [TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity]. Pagotto U; Vanuzzo D; Vicennati V; Pasquali R G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755 [TBL] [Abstract][Full Text] [Related]
3. Orlistat: a review of its use in the management of obesity. Hvizdos KM; Markham A Drugs; 1999 Oct; 58(4):743-60. PubMed ID: 10551441 [TBL] [Abstract][Full Text] [Related]
4. Orlistat--a novel weight loss therapy. Lucas KH; Kaplan-Machlis B Ann Pharmacother; 2001 Mar; 35(3):314-28. PubMed ID: 11261530 [TBL] [Abstract][Full Text] [Related]
5. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Leung WY; Thomas GN; Chan JC; Tomlinson B Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112 [TBL] [Abstract][Full Text] [Related]
6. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Finer N; James WP; Kopelman PG; Lean ME; Williams G Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623 [TBL] [Abstract][Full Text] [Related]
7. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380 [TBL] [Abstract][Full Text] [Related]
8. Orlistat. Wong NN; Cheng-Lai A Heart Dis; 2000; 2(2):174-81. PubMed ID: 11728255 [TBL] [Abstract][Full Text] [Related]
9. Orlistat: its current status as an anti-obesity drug. Ballinger A; Peikin SR Eur J Pharmacol; 2002 Apr; 440(2-3):109-17. PubMed ID: 12007529 [TBL] [Abstract][Full Text] [Related]
10. Spotlight on orlistat in the management of patients with obesity. Curran MP; Scott LJ Treat Endocrinol; 2005; 4(2):127-9. PubMed ID: 15783249 [TBL] [Abstract][Full Text] [Related]
11. Orlistat: a review of its use in the management of patients with obesity. Curran MP; Scott LJ Drugs; 2004; 64(24):2845-64. PubMed ID: 15563254 [TBL] [Abstract][Full Text] [Related]
12. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204 [TBL] [Abstract][Full Text] [Related]
13. Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study. Shirai K; Tanaka M; Fujita T; Fujii Y; Shimomasuda M; Sakai S; Samukawa Y Adv Ther; 2019 Jan; 36(1):217-231. PubMed ID: 30387022 [TBL] [Abstract][Full Text] [Related]
14. Orlistat: current status in clinical therapeutics. McClendon KS; Riche DM; Uwaifo GI Expert Opin Drug Saf; 2009 Nov; 8(6):727-44. PubMed ID: 19998527 [TBL] [Abstract][Full Text] [Related]